Damora Therapeutics, Inc. (DMRA) Stock Score, Valuation & Financial Research

Damora Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for DMRA

Damora Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 21.28. These figures are a research snapshot, not a buy or sell recommendation.

What Damora Therapeutics, Inc. does

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Damora Therapeutics is a biopharmaceutical company currently in the development stage. It does not generate revenue from product sales and instead funds its operations through equity financing, including private placements and public offerings, to advance its pipeline of mutant calreticulin-targeted therapeutics.

Products and services

  • The company is developing a pipeline of differentiated therapeutics for hematological malignancies, including lead candidate DMR-001, as well as DMR-002 and DMR-003, targeting mutCALR-driven myeloproliferative neoplasms.

Customer types

Patients with blood disorders.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on unnamed third-party contract research organizations to conduct its preclinical and clinical trials. Source

Business strengths to evaluate

  • Pipeline of differentiated therapeutics targeting mutCALR-driven MPNs Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Need for additional capital to fund research and development Source

Sources: Company research source · Pipeline of differentiated therapeutics targeting mutCALR-driven MPNs

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

DMRA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 21.28
Market capitalization:
1.31B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -262.83M
Free cash flow:
USD -6.73M
Cash:
USD 540.52M
Total debt:
USD 68K
EPS:
USD -124.78

What stands out

  • Free cash flow is USD -6.73M, negative for the stored period.
  • The balance sheet shows USD 540.52M of cash versus USD 68K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 540.45M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for DMRA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can DMRA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is DMRA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for DMRA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of DMRA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research DMRA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.